Why isn’t such hate speech removed from here :crossed_
12 Likes
The deal will come if it’s meant to, assuming it comes at all. The adequacy of the funds has been discussed quite a bit here, so by reading the posts, that will also become clear. If everyone vents their feelings and tension on this board, it will lose its value.
7 Likes
But should hate speech directed at an individual be tolerated here? If one is wrong and not in line with the general consensus? I’ll take screenshots of these, and they’ll be shared more widely again, thanks!
1 Like
Hra Bono hehkuttaa:
Petri BonoPetri Bono • 3rd+Verified • 3rd+Chief Medical Officer at Faron PharmaceuticalsChief Medical Officer at Faron Pharmaceuticals7h • 7 hours ago • Visible to anyone on or off LinkedIn
Follow
Great to see the field moving forward. In their November editorial “New hope, old challenges in myelodysplastic syndromes”, The Lancet Haematology discusses how improved trial design and strong global collaboration are starting to shape the next generation of therapies in higher-risk MDS — and specifically references FDA feedback refining the registrational development path for bexmarilimab. Proud to see Bexmarilimab recognised in this context.
20 Likes
My assessment is that BTD is expected from the FDA for a certain part, and this triggers certain better terms in the partnering. So, likely with one or more candidates, there are options for different development paths, and I believe that a competitive situation is underway and the stakes are being raised. So, for now, time is still on Faron’s side.
Early December will be really interesting; the FDA decision is a kind of deadline, and then situations will quickly become clearer. It would be nice to read about partnering at ASH 
14 Likes
Hopefully the US government shutdown would end soon, it seems to be slowing down processes. A couple of BTDs have occurred during the shutdown, the latest on October 9th (Cidara/CD388), but it has been quiet since then.
2 Likes
We are kept in the dark and just move forward in the thickening fog. The fact is, however, that Syrjälä is adding and the top 30 (over 50% of the votes) consider the ride (and visibility?) good at least for now. Trust is starting to wear thin, but reason still says that patience is a virtue. Indeed, those statements will have to be accounted for one way or another if solutions are not made public VERY SOON. Then (someday) we will get to evaluate the “output”..
4 Likes
Note again how the forum is running wild with fears that a partner won’t be found. However, an investment bank (possibly Stifel, as brought up by ValkeoinenPeuran?) has been brought in to handle the deal.
The deal is quite complex, however. How much money will go to Faron and what rights are included in the package? Blood cancers or the entire Bex patent portfolio? And how much is paid for what at which stage? And with whom, ultimately, will a deal be made?
Last time, the entire Bex was at such an early stage of research that the offered deals were not attractive enough. And I’m not surprised, as at that stage there was much less information about the possibility of success. And there are still no guarantees now, but the chances of success have significantly increased with the progress of research and FDA statements.
In my opinion, JJ’s latest talks about solids and their potential from Bex’s perspective suggest that Faron aims to make a deal with potential partners where Bex is brought to market through research into blood cancers. If Faron is correct in its hypothesis, the same mechanism that can be verified in blood cancers would very likely be replicable in cancers with a similar Clever-1 microenvironment. And many of these, like the blood cancers studied, are those for which current treatments are not very effective (e.g., pancreatic cancer). In my opinion, the market lies precisely in this, and I believe a potential partner would also come to the same conclusion.
I myself am not worried that a partnership won’t be achieved. This is such a potential product. Even though there is still research left and things to prove. Deals have been made with much weaker starting points.
And even though questions (some of them justified) have been raised here about the research, Finnish (cancer) research is of such high quality that I would not consider the quality of the research to be a very significant risk factor.
38 Likes
At what price would Clarkki buy Faron?
I understand that you think it’s still too early to make an investment decision because there is too little information about the drug’s efficacy. But in light of current information, at what market value (e.g., 0, 50, 100, or 150 M€) would Faron be an attractive acquisition target in your opinion?
However, you are here almost daily, so clearly you have some interest in Faron, even though you are cautious and strongly doubt the drug’s efficacy, and you ponder whether the possible effect is, after all, due to AZA.
5 Likes
Agree about hate speech. Everyone has the right to write opinions here, whether bullish or bearish.
Regarding the dwindling cash and the deal deadline, I think that the deal will come, if it’s going to come, either in early December or, if there are delays, it will stretch into January. Investors’ nervousness follows its own path, and the deal’s refinement follows its own. Uncertainty just has to be tolerated, or one should reduce risk/sell all shares.
11 Likes
A terrible disappointment will be a rights issue after all this hype. However, isn’t it probably the most likely option?
3 Likes
Possible, but in my opinion unlikely. I would guess that HCM will go to the “backup fund” if funding doesn’t come from elsewhere.
Edit: Was the offering even possible? When listed on the London and Helsinki stock exchanges.
A share issue would be a complete disaster for Faron’s credibility and thereby for the stock. Given that the sentiments are already like this, a share issue is the absolute last thing and would certainly scare away many investors. I personally added to my Faron position yesterday, and therefore I don’t believe in the possibility of a share issue. I believe some kind of deal will come without even needing to resort to further funding rounds.
I also believe that everyone has the right to their own opinion, but then the treatment should be the same for all opinions. Now Faron can be freely criticized, but hyping it up is advertising and leads to flagging. One must be careful whether one presents things as facts or as one’s own opinions.
6 Likes
A rights issue will not happen because, due to the dual listing, it cannot be done, at least not at reasonable costs and in practice. The matter was discussed in connection with the “hiccup” and the “euro issue”. So, regarding the issue, the alternatives are a directed issue or a public offering. I refer to Juho’s comments in the last webcast. I believe that Juho has an idea of how the presumably larger financing, needed soon, will be arranged. He asked us to evaluate after things became clear, “how did we deliver?”. In my opinion, he wouldn’t throw out such a sentence if the solution in Juho’s mind were a large public offering or even resorting to a backup fund. In my opinion, there is some transaction that is already ready when announced and thus brings a sufficient amount of money into the cash register. So, for example, partnering, licensing, selling a piece (of the company/asset), or a large directed issue that has already been agreed upon. (Of course, a deal can always fall through at the last minute, even if it was almost certain in Juho’s mind.)
13 Likes
A share issue would scare away stock speculators and those seeking quick profits. That would be purely a positive thing. For long-term investors who trust Faron and BEX, it makes no difference whether the partnering happens by the end of the year or, for example, next summer. A share issue is a perfectly good way to finance operations until the right partner is found. I myself will participate in a share issue if given the opportunity. There’s no rush. The patents are valid for a long time, and F3 can be started, at least in some parts, with our own funds. Then, when Phase 3 is underway, and a partner still can’t be found, that’s when things start to get a bit shaky, because without a partner, it won’t be completed within a reasonable timeframe.
Quite a strong reaction to a slightly heated debate. I, for one, have never read any “hate speech” here. One shouldn’t be too sensitive; especially on the internet. And of course, it’s desirable that the parties involved get offended if someone gets offended. Let’s leave out the vicarious offense, so there won’t be unnecessary drama.
18 Likes
Approaching useless speculation, but I myself would hope to see a situation where Faron, first of all, either through a significant license deal upfront payment or a large share issue, would reach a financial position where all planned studies could be started immediately at 100% efficiency.
It is often repeated here that the greatest value lies in the treatment of solid tumors, etc. However, this cannot be realized until that data is produced. It’s far too slow a route to proceed only in MDS and then gradually initiate other indications with the help of a milestone.
It is true that BLAZE and BEXAR and FINPROVE are in the pipeline, but they are investigator-initiated. At least I have not received information on whether they are suitable for Phase 1 studies in a regulatory sense, what their design is, or whether dialogue has been held with the EMA and FDA. Most likely, they are not. So, things are progressing too slowly.
So, 100 million would be needed in cash. On top of that, I could pay 100 million in enterprise value.
It may be that the market will sometimes offer a buying opportunity; biotechs are very volatile, and Faron has been calmer in its movements than usual so far.
30 Likes
So, in other words, when the market value is now 250 million, would you be willing to pay 100+100 for the company when 100 million in funding is secured?
So, the target price would therefore be around one euro? when the current share price is about 2.25?
This is what it ultimately comes down to; a deal can be made even today, but the price might not be satisfactory. So, statements about a deal coming in x months don’t automatically mean a cash grab. It depends on how eager the bidders are.
2 Likes
Right, thank you for your answer. I personally see that in this case, it’s about whether one can draw conclusions based on the current uncertain information about whether Bex works or not. In any case, the near future will strongly shape the company’s valuation one way or another.
I don’t believe that at the point when the data is already clear, one can still gain an advantage or “beat the market”. Especially the next moments will, in my opinion, determine whether the drug works, i.e., whether it gets market approval through
3 Likes
I haven’t watched the latest webcast, but “deliver” certainly refers to a positive outcome. E.g., Lauri Markkanen delivered with 51 points."
7 Likes
If we start splitting hairs, then “deliver” in English is a very versatile and polysemous word, which in itself does not refer to positive or negative. If Markkanen had scored 15 points in the game, the verb “deliver” could have been used for that too. In Faron’s case, the word gets its meaning from the context of use, i.e., what else has been stated in the same sentence. Is this “deliver” remark on some video or where can it be found?
4 Likes